Alana Hippensteele is lead editor at Pharmacy Times®, Contemporary Clinic, and Pharmacy Times Oncology Edition®. She has a master's in Critical Theory and Creative Research from Pacific Northwest College of Art and a bachelor's degree in English and Art History. She has worked as an English instructor at Temple University and held editorial positions at American Cleaning & Hygiene and Tin House.
Fun Fact: Unfortunately, Chainsaws Were Invented for Childbirth
March 26th 2021Although childbirth remains a difficult, often stressful experience for mothers, the advent of opioid medications for labor pain relief and the use of appropriate sanitation methods has made childbirth far safer for mothers than was possible during previous periods in history.
Read More
Fauci: DSMB Challenge of New AstraZeneca COVID-19 Vaccine Data Is an ‘Unfortunate Incident’
March 23rd 2021Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.
Read More
Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate Commences Enrollment in the US, Canada
March 23rd 2021Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate in combination with a pandemic adjuvant commenced following approval to proceed with participant enrollment from regulatory authorities in both Canada and the United States.
Read More
First Participants Dosed in Phase 2/3 Study on Moderna’s COVID-19 Vaccine in Pediatric Population
March 22nd 2021The first participants were dosed in the phase 2/3 KidCOVE study investigating vaccine candidate mRNA-1273 against COVID-19 in children aged 6 months to less than 12 years of age.
Read More
Clinical Trial Confirms Nasal Spray Efficacy in Treating, Reducing Transmission of COVID-19
March 18th 2021Results of clinical trials have shown that a nitric oxide nasal spray is both a safe and effective antiviral treatment to prevent COVID-19 transmission and symptom duration, as well as reduce symptom severity and damage in those already infected.
Read More
FDA Grants MK-6482 NDA Priority Review for von Hippel-Lindau Disease-Associated RCC
March 17th 2021The FDA has granted priority review for an NDA for the hypoxia-inducible factor-2 alpha inhibitor MK-6482 for the potential treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma that does not require immediate surgery.
Read More
Walgreens Announces the Successful Administration of 5 Million COVID-19 Vaccinations
March 9th 2021In a recent statement, Walgreens announced that it has administered approximately 5 million COVID-19 vaccinations at long-term care facilities, in its stores, and through its vaccination clinics.
Read More